MRK

Merck & Co Inc

Add to Watchlist

Advanced Chart

75.970

-1.680(-2.160%)

Overview
Forecast
Valuation

Line

Candle

YTD

High

78.450

Open

77.960

VWAP

76.59

Vol

15.61M

Mkt Cap

190.76B

Low

75.820

Amount

1.20B

EV/EBITDA(TTM)

7.62

Total Shares

2.51B

216.44B

EV/OCF(TTM)

10.37

P/S(TTM)

3.02

Merck & Co., Inc. is a global health care company. It offers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceuticals and vaccine products. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. It sells these human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, and health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s lead candidate, MK-6070, is a T-cell engager targeting delta-like ligand 3 (DLL3), an inhibitory canonical Notch ligand.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

16.47B

+5.4%

2.198

+27.82%

17.14B

+2.92%

2.453

+56.26%

15.86B

-1.55%

2.053

-9.94%

Estimates Revision

The market is revising Downward the revenue expectations for Merck & Co., Inc. (MRK) for FY2025, with the revenue forecasts being adjusted by -0.45% over the past three months. During the same period, the stock price has changed by -11.32%.

Revenue Estimates for FY2025

Revise Downward

-0.45%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-0.64%

In Past 3 Month

Stock Price

Go Down

-11.32%

In Past 3 Month

17 Analyst Rating

35.42% Upside

Wall Street analysts forecast MRK stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRK is 102.88 USD with a low forecast of 82.00 USD and a high forecast of 138.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

10 Buy

7 Hold

0 Sell

Moderate Buy

35.42% Upside

Current: 75.970

Low

82.00

Averages

102.88

High

138.00

35.42% Upside

Current: 75.970

Low

82.00

Averages

102.88

High

138.00

Cantor Fitzgerald

Carter Gould

Hold

Initiates

$85

2025-04-22

Reason

Cantor Fitzgerald

Carter Gould

Price Target

$85

2025-04-22

Initiates

Hold

Reason

Guggenheim

Vamil Divan

Strong Buy

Reiterates

$115

2025-04-17

Reason

Guggenheim

Vamil Divan

Price Target

$115

2025-04-17

Reiterates

Strong Buy

Reason

Deutsche Bank

James Shin

Strong Buy

Hold

Downgrades

$128 → $105

2025-02-18

Reason

Deutsche Bank

James Shin

Price Target

$128 → $105

2025-02-18

Downgrades

Strong Buy

Hold

Reason

Guggenheim

Vamil Divan

Strong Buy

Maintains

$122 → $115

2025-02-12

Reason

Guggenheim

Vamil Divan

Price Target

$122 → $115

2025-02-12

Maintains

Strong Buy

Reason

Guggenheim analyst Vamil Divan lowered the firm's price target on Merck to $115 from $122 and keeps a Buy rating on the shares. The firm is updating its company model following Q4 earnings and the company's initial FY25 guidance, noting that its lower target is mainly driven by lower sales estimates for Gardasil, partially offset by higher expectations on management's ability to execute on converting patients to subcutaneous Keytruda.

Morgan Stanley

Terence Flynn

Hold

Maintains

$113 → $106

2025-02-05

Reason

Morgan Stanley

Terence Flynn

Price Target

$113 → $106

2025-02-05

Maintains

Hold

Reason

Morgan Stanley analyst Terence Flynn lowered the firm's price target on Merck to $106 from $113 and keeps an Equal Weight rating on the shares. The company's 2025 guidance came in below expectations as Gardasil demand in China remains weak and the firm is reducing its estimates, thought more broadly, the focus remains on the Keytruda tail / loss of exclusivity and the progress with Merck's pipeline efforts, the analyst tells investors in a research note.

Citigroup

Andrew Baum

Strong Buy

Maintains

$125 → $115

2025-02-05

Reason

Citigroup

Andrew Baum

Price Target

$125 → $115

2025-02-05

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Merck & Co Inc (MRK.N) is 8.44, compared to its 5-year average forward P/E of 17.32. For a more detailed relative valuation and DCF analysis to assess Merck & Co Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

17.32

Current PE

8.44

Overvalued PE

31.89

Undervalued PE

2.76

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

11.93

Current EV/EBITDA

6.99

Overvalued EV/EBITDA

16.75

Undervalued EV/EBITDA

7.11

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Undervalued

5Y Average PS

4.17

Current PS

2.91

Overvalued PS

4.66

Undervalued PS

3.67

Financials

Annual

Quarterly

FY2025Q1

YoY :

-1.56%

15.53B

Total Revenue

FY2025Q1

YoY :

-8.66%

5.97B

Operating Profit

FY2025Q1

YoY :

+6.67%

5.09B

Net Income after Tax

FY2025Q1

YoY :

+7.49%

2.01

EPS - Diluted

FY2025Q1

YoY :

-47.42%

1.17B

Free Cash Flow

FY2025Q1

YoY :

-0.10%

78.21

Gross Profit Margin - %

FY2025Q1

YoY :

+48.28%

26.66

FCF Margin - %

FY2025Q1

YoY :

+8.37%

32.75

Net Margin - %

FY2025Q1

YoY :

+586.84%

23.49

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

352.7K

USD

3-6

Months

1.4M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

1.6M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

840.7K

Volume

6-9

Months

0.0

Volume

0-12

Months

2.5M

Volume

Bought

0-3

0.0

Volume

Months

3-6

4.2M

Volume

Months

6-9

0.0

Volume

Months

0-12

10.3M

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

105.5K

USD

3-6

Months

154.0K

USD

6-9

Months

123.5K

USD

0-12

Months

8.0K

USD

Bought

0-3

88.5K

USD

Months

3-6

146.0K

USD

Months

6-9

16.0K

USD

Months

0-12

16.0K

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

352.7K

USD

3-6

Months

1.4M

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

1.6M

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MRK News & Events

Events Timeline

2025-05-08 (ET)

2025-05-08

07:26:07

Merck Animal Health and State of Kansas announce $895M investment

2025-05-06 (ET)

2025-05-06

13:35:55

FDA announces expanded use of unannounced inspections at foreign facilities

2025-05-05 (ET)

2025-05-05

15:13:10

Trump to sign order streamlining U.S. drug manufacturing regulations, WaPo says

News

8.0

08:32 AMBenzinga

Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket

5.0

05:00 AMNewsfilter

Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal

3.0

05-11NASDAQ.COM

Guru Fundamental Report for MRK

People Also Watch

ATAI Life Sciences NV

Alliance Entertainment Holding Corp

Transcontinental Realty Investors Inc

Eledon Pharmaceuticals Inc

Metalla Royalty & Streaming Ltd

3.060

USD

+3.03%

FAQ

What is Merck & Co Inc (MRK) stock price today?

The current price of MRK is 75.97 USD — it has decreased -2.16 % in the last trading day.

MRK

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

MRK News & Events

Events Timeline

News

People Also Watch

FAQ

What is Merck & Co Inc (MRK) stock price today?

What is Merck & Co Inc (MRK)'s business?

What is the price predicton of MRK Stock?

What is Merck & Co Inc (MRK)'s revenue for the last quarter?

What is Merck & Co Inc (MRK)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Merck & Co Inc (MRK)'s fundamentals?

How many employees does Merck & Co Inc (MRK). have?

What is Merck & Co Inc (MRK) market cap?